This is a KP.2 news story, published by Yahoo, that relates primarily to Pfizer news.
For more KP.2 news, you can click here:
more KP.2 newsFor more Pfizer news, you can click here:
more Pfizer newsFor more vaccine development news, you can click here:
more vaccine development newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
immunization campaign. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest vaccine news, older shots news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
vaccinesReuters
•81% Informative
Vaccine makers say their 2024-25 vaccines could neutralize newer subvariants such as KP.2 much better than the older shots.
FDA panel will vote to recommend if companies should target the JN.1 variant.
Pfizer and Moderna said they are ready to supply vaccines that target J.1 or KP.1.
Novavax has said it would be able to offer a vaccine in the United States this autumn if regulators accept the shot it started manufacturing.
VR Score
92
Informative language
98
Neutral language
65
Article tone
formal
Language
English
Language complexity
54
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links